Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 14/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 14/20 | 0.73 |
| ▸ | NPC1 | O15118 | 6/20 | 0.73 |
| ▸ | RAB9A | P51151 | 5/20 | 0.73 |
| ▸ | POLB | P06746 | 7/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.64 |
| ▸ | CCR6 | P51684 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.61 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | XBP1 | P17861 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | HTT | P42858 | 4/20 | 0.60 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.60 |
| ▸ | AHR | P35869 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9290406 | 0.88 | MEN1 (0.61) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL7709407 | 0.84 | KMT2A (1.00) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL13495357 | 0.84 | MEN1 (0.68) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL10018568 | 0.84 | MEN1 (0.68) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL14560563 | 0.82 | MEN1 (0.76) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL7484059 | 0.82 | MEN1 (0.61) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL7485990 | 0.82 | MEN1 (0.61) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL14257646 | 0.82 | MEN1 (0.69) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL14067864 | 0.81 | MEN1 (0.68) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL29903439 | 0.81 | MEN1 (0.68) | MEN1KMT2ANPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0560447-B1 | Thermoplastic composition based on polyphenylene ether and polyamide | ENICHEM SPA (IT) | 1998-05-13 | — | — | EP | claimed |
| EP-0534543-B1 | Polyphenylene ether containing reactive end groups, process for preparing it and relevant thermoplastic compositions | ENICHEM SPA (IT) | 1997-12-17 | — | — | EP | claimed |
| CN-107417616-A | Methods and compositions for treating beta-thalassemia and sickle cell disease | 中央研究院 | 2017-12-01 | — | — | CN | disclosed |
| US-20170290820-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2017-10-12 | — | — | US | disclosed |
| US-20170290820-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2017-10-12 | — | — | US | disclosed |
| US-20170290820-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2017-10-12 | — | — | US | disclosed |
| US-9662324-B2 | Methods and compositions for treating β-thalassemia and sickle cell disease | ACADEMIA SINICA (TW) | 2017-05-30 | — | — | US | disclosed |
| US-9662324-B2 | Methods and compositions for treating β-thalassemia and sickle cell disease | ACADEMIA SINICA (TW) | 2017-05-30 | — | — | US | disclosed |
| US-9662324-B2 | Methods and compositions for treating β-thalassemia and sickle cell disease | ACADEMIA SINICA (TW) | 2017-05-30 | — | — | US | disclosed |
| US-20160106728-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2016-04-21 | — | — | US | disclosed |
| US-20160106728-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2016-04-21 | — | — | US | disclosed |
| US-20160106728-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2016-04-21 | — | — | US | disclosed |
| CN-105492428-A | Methods and compositions for treating beta-thalassemia and sickle cell disease | ACADEMIA SINICA | 2016-04-13 | — | — | CN | disclosed |
| WO-2014179567-A2 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179567-A2 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290820-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | HBB, HBZ, HBG1 | MEN1 1989/4885KMT2A 2095/4885NPC1 687/4885 |
| US-20160106728-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | HBB, HBZ, HBG1 | MEN1 1989/4885KMT2A 2095/4885NPC1 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.